Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head?

HPB

Volumn 15, Issue 11, 2013, Pages 872-881

  Petermann, David ^a   Demartines, Nicolas ^a   Schäfer, Markus ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATICODUODENECTOMY; PATIENT SELECTION; SUPERIOR MESENTERIC ARTERY; TUMOR VOLUME; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR BURDEN;

EID: 84886092649     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12052     Document Type: Article

References (46)

1. Winter JM, Brennan MF, Tang LH, D'Angelica MI, Dematteo RP, Fong Y, et al. (2012) Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol 19: 169-175.
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M,. (2011) Pancreatic cancer. Lancet 378: 607-620.
3. Winter JM, Cameron JL, Olino K, Herman JM, de, Jong MC, Hruban RH, et al. (2010) Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg 14: 379-387.
4. Choi SB, Park SW, Kim KS, Choi JS, Lee WJ,. (2009) The survival outcome and prognostic factors for middle and distal bile duct cancer following surgical resection. J Surg Oncol 99: 335-342.
5. Park HS, Lee JM, Choi HK, Hong SH, Han JK, Choi BI,. (2009) Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT. J Magn Reson Imaging 30: 586-595.
6. Tamm EP, Balachandran A, Bhosale PR, Katz MH, Fleming JB, Lee JH, et al. (2012) Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am 50: 407-428.
7. Schafer M, Mullhaupt B, Clavien PA,. (2002) Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg 236: 137-148.
8. Teh SH, Diggs BS, Deveney CW, Sheppard BC,. (2009) Patient and hospital characteristics on the variance of perioperative outcomes for pancreatic resection in the United States: a plea for outcome-based and not volume-based referral guidelines. Arch Surg 144: 713-721.
9. McPhee JT, Hill JS, Whalen GF, Zayaruzny M, Litwin DE, Sullivan ME, et al. (2007) Perioperative mortality for pancreatectomy: a national perspective. Ann Surg 246: 246-253.
10. Finks JF, Osborne NH, Birkmeyer JD,. (2011) Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364: 2128-2137.
11. Topal B, Van de Sande S, Fieuws S, Penninckx F,. (2007) Effect of centralization of pancreaticoduodenectomy on nationwide hospital mortality and length of stay. Br J Surg 94: 1377-1381.
12. de Wilde RF, Besselink MG, van der, Tweel I, de, Hingh IH, van, Eijck CH, Dejong CH, et al. (2012) Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg 99: 404-410.
13. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200-1210.
14. Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, et al. (2009) Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 100: 246-250.
15. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
16. Trouilloud I, Dubreuil O, Boussaha T, Lepere C, Landi B, Zaanan A, et al. (2011) Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol 35: 364-374.
17. Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A,. (2010) AJCC Cancer Staging Manual, 7th edn. Chicago: Springer.
18. Brennan MF, Kattan MW, Klimstra D, Conlon K,. (2004) Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 240: 293-298.
19. Helm J, Centeno BA, Coppola D, Melis M, Lloyd M, Park JY, et al. (2009) Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer. Cancer 115: 4080-4089.
20. Ferrone CR, Kattan MW, Tomlinson JS, Thayer SP, Brennan MF, Warshaw AL,. (2005) Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol 23: 7529-7535.
21. Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, et al. (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254: 311-319.
22. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F,. (2012) Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148: 362-375.
23. Yeo CJ,. (2000) The Johns Hopkins experience with pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. J Gastrointest Surg 4: 231-232.
24. Hsu PK, Huang HC, Hsieh CC, Hsu HS, Wu YC, Huang MH, et al. (2007) Effect of formalin fixation on tumor size determination in stage I non-small cell lung cancer. Ann Thorac Surg 84: 1825-1829.
25. Fleming ID, Cooper JS, Henson DE, Hutter RV, Kennedy BJ, Murphy GP, et al. (1997) AJCC Cancer Staging Manual, 5th edn. Philadelphia: Lippincott-Raven.
26. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. (2002) AJCC Cancer Staging Manual, 6th edn. Chicago: Springer.
27. Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, et al. (2007) Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 110: 738-744.
28. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP,. (2008) Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 9: 99-132.
29. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. (1997) Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 226: 248-257; discussion 257-260.
30. Benassai G, Mastrorilli M, Quarto G, Cappiello A, Giani U, Forestieri P, et al. (2000) Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 73: 212-218.
31. Lim JE, Chien MW, Earle CC,. (2003) Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237: 74-85.
32. Takai S, Satoi S, Toyokawa H, Yanagimoto H, Sugimoto N, Tsuji K, et al. (2003) Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas 26: 243-249.
33. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10: 1199-1210; discussion 1210-1191.
34. Chen JW, Bhandari M, Astill DS, Wilson TG, Kow L, Brooke-Smith M, et al. (2010) Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB 12: 101-108.
35. Jamieson NB, Denley SM, Logue J, Mackenzie DJ, Foulis AK, Dickson EJ, et al. (2011) A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol 18: 2318-2328.
36. de Jong MC, Li F, Cameron JL, Wolfgang CL, Edil BH, Herman JM, et al. (2011) Re-evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol 103: 656-662.
37. Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, et al. (2012) Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 118: 2674-2681.
38. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J,. (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7: e1000267.
39. Heinrich S, Schafer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, et al. (2008) Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 248: 1014-1022.
40. Papalezova KT, Tyler DS, Blazer DG, 3rd, Clary BM, Czito BG, Hurwitz HI, et al. (2012) Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol 106: 111-118.
41. Tummala P, Junaidi O, Agarwal B,. (2011) Imaging of pancreatic cancer: an overview. J Gastrointest Oncol 2: 168-174.
42. Shrikhande SV, Barreto SG, Goel M, Arya S,. (2012) Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature. HPB 14: 658-668.
43. Geier A, Nguyen HN, Gartung C, Matern S,. (2000) MRCP and ERCP to detect small ampullary carcinoma. Lancet 356: 1607-1608.
44. Artifon EL, Couto D, Jr, Sakai P, da Silveira EB,. (2009) Prospective evaluation of EUS versus CT scan for staging of ampullary cancer. Gastrointest Endosc 70: 290-296.
45. Li N, Liu C, Bi W, Lin X, Jiao H, Zhao P,. (2012) MRCP and 3D LAVA imaging of extrahepatic cholangiocarcinoma at 3 T MRI. Clin Radiol 67: 579-586.
46. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A,. (2006) Redefining the R1 resection in pancreatic cancer. Br J Surg 93: 1232-1237.